Founded in 2022 by Population Health Partners and ARCH Venture Partners, the biotech venture giant led by Bob Nelsen, Metsera ...

Metsera, Inc. is at the center of a bidding war between Novo Nordisk and Pfizer, driving its stock up 20%. Learn more about ...

In a Phase I trial, biomarkers seem to suggest the potential for a once or twice yearly dosing of Wave’s siRNA for weight ...

Exclusive: Australian doctors are being approached every day by teenagers and young adults – girls as well as boys – asking ...

"GLP-1RA microdosing trend continues despite “anecdotal evidence”" was originally created and published by Pharmaceutical ...

An expert said weight loss drugs might help people see faster results, which can give them encouragement to continue. But he ...

Eli Lilly’s blockbuster drug Mounjaro has quickly become the market leader in the segment, thanks to its strong clinical performance and early entry advantage.

A new Gallup poll indicates that the obesity rate among U.S. adults has declined over the past three years as the number of ...

Despite success with injectable drugs pharma companies are investing heavily in tablets, long considered the holy grail of ...

The bears will point out that Novo Nordisk is losing ground in the GLP-1 market to its most important competitor, Eli Lilly.

Lilly’s quarterly results Thursday, combined with Novo Nordisk’s unsolicited offer for a startup, confirm the $72 billion ...

Insider buys can be a telltale sign of a turnaround, as these investments give you a window into where management stands with ...